In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Endomatrix Inc.

http://www.endomatrix.com

Latest From Endomatrix Inc.

What's Hot in Devices: A Physicians' View

A set of doctors' perspectives on what clinicians see as emerging device technologies in cardiology, orthopedics, and neurology. This article is excerpted from Windhover Information's annual START-UP Forum, held this year in the beginning of April in Boston, titled "Bringing Follow-on Funding to Heatlh Care."

Innovation Platform Technologies

Device Adoption Through Physicians' Eyes

Windhover Information's annual START-UP Forum, held this year in the beginning of April in Boston, was titled "Bringing Follow-on Funding to Heatlh Care," and featured a clinicians' roundtable discussion that examined new opportunities in medical devices. This article features excerpts from this discussion focused on what clinicians in cardiology, orthopedics, and neurology are looking for from device companies, feedback that can help spur adoption.

Medical Device Innovation

Endothelial Dysfunction: A Drug Opportunity as Big as All Heart Disease

Less than 50% of coronary artery disease is attributable to the known risk factors-such as smoking, obesity, diabetes, family history of heart disease, and high cholesterol. That's why researchers and companies are beginning to take a close look at endothelial dysfunction, a disorder of the lining of the arteries that causes vessels to fail to expand normally in response to increased blood flow. Endothelial dysfunction is widely recognized in the clinical community as the earliest detectable harbinger of heart disease, one that would help physicians address patients before they have their first heart attack or stroke. But even more than that, many now see the disorder as a reversible condition that should be treated in its own right, to avoid the future deadly consequences of chronic inflammation, clot formation, plaque deposition, or plaque rupture. Because it's still early days for the field, Endomatrix Inc. has chosen a combination nutraceutical/pharmaceutical development path. It is getting early clinical experience in patients by testing and commercializing a proprietary dietary supplement, while at the same time developing new drugs that target endothelial dysfunction.

BioPharmaceutical

Eberhard Grube: European Champion of Device Development

An interview with Eberhard Grube, one of Germany's leading interventional cardiologists and a pioneer in medical devices who's had a role in changing the mindset of European physicians to bring together clinical practice and new product development. Grube discusses the role of the physician as clinical investigator, and the European perspective on product development.

Medical Device Europe
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Nutraceuticals
UsernamePublicRestriction

Register